Market Overview

Moleculin Biotech's Volatility, Explained

Moleculin Biotech's Volatility, Explained
Benzinga's Top Upgrades, Downgrades For November 14, 2018
The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut
Microcaps dominate midday movers (Seeking Alpha)

Moleculin Biotech Inc (NASDAQ: MBRX)’s good-news rally had a short life.

The stock popped 55 percent Thursday after management announced a “breakthrough” discovery of a molecule capable of shutting down tumor activity and treating cancer.

But the stock took a 26-percent downturn Friday after Moleculin announced a $9 million offering and inspired profit-taking.

The series of events wasn’t unusual.

Companies, particularly pharmaceuticals and biotechs, commonly issue offerings off rallies to capitalize on the elevated prices and secure financing at a stronger valuation. Those funds can then advance research and development in yet unprofitable pipelines to set the stage for additional positive reports and more sustainable corresponding rallies.

However, the dilutive offering is poorly perceived by shareholders, whose holdings lose value as supply expands. Investors, then, tend to react by selling on the highs.

Such activity was seen this week in both Dare Bioscience Inc (NASDAQ: DARE) and Aytu Bioscience Inc (NASDAQ: AYTU), which fell 40 percent and 27 percent, respectively, on offering reports.

Moleculin saw fluctuation between $1.82 and $3.25 over the last few sessions, and shares stabilized around $2.08 Friday afternoon.

Related Links:

One Of The Creators Of The VXX Explains The Problem With Many Volatility Products

A Day Trader's Guide To Interpreting Volume

Posted-In: Biotech News Education Offerings Top Stories General Best of Benzinga


Related Articles (AYTU + DARE)

View Comments and Join the Discussion!

In An Underwhelming Rail Supply Sector, Trinity Industries Is A Buy, Says Wells Fargo

Credit Suisse: Trump Budget, Guidance Are Tailwinds For Huntington Ingalls